Related Experiment Video
Updated: Aug 30, 2026
Gene-environment Interaction Models to Unmask Susceptibility Mechanisms in Parkinson's Disease
Published on: January 7, 2014
COX-2-deficient mice are less prone to MPTP-neurotoxicity than wild-type mice
Zhehui Feng1, Dongdong Li, Peter C W Fung
1University Department of Medicine, University of Hong Kong, Queen Mary Hospital, Hong Kong. zfeng@mdanderson.org
Abstract:
The primary lesion in Parkinson's disease is the death of dopaminergic neurons in the substantia nigra. The role of cyclooxygenase (COX)-2 in the etiology of Parkinson's disease was explored using COX-2 gene knockout mice. Mortality after injection of 1-methyl-4-phenyl-1,2,3,6 tetrahydropyridine (MPTP, a chemical known to cause parkinsonism in humans) in heterozygous COX-2-deficient mice was lower than that in wild-type mice. The number of tyrosine hydroxylase immunoreactive neurons in the substantia nigra pars compacta of MPTP-treated wild-type mice declined to a greater extent than in heterozygous mice. Inhibition of COX-2 protein expression decreased the lesion caused by MPTP and protected the dopaminergic neurons in substantia nigra pars compacta. This result suggested that inhibition of COX-2 has potential therapeutic implications.
Insights
Cyclooxygenase-2 (COX-2) inhibition may protect against Parkinson's disease. Studies using COX-2 deficient mice showed reduced mortality and preserved dopaminergic neurons after MPTP exposure, suggesting therapeutic potential.
Area of Science:
- Neuroscience
- Pharmacology
Background:
- Parkinson's disease involves the degeneration of dopaminergic neurons in the substantia nigra.
- The role of cyclooxygenase-2 (COX-2) in Parkinson's disease pathogenesis is not fully understood.
Purpose of the Study:
- To investigate the role of COX-2 in Parkinson's disease using a mouse model.
- To determine if inhibiting COX-2 offers neuroprotection against MPTP-induced parkinsonism.
Main Methods:
- Utilized COX-2 gene knockout mice and wild-type littermates.
- Administered 1-methyl-4-phenyl-1,2,3,6 tetrahydropyridine (MPTP) to induce parkinsonian symptoms.
- Assessed mortality rates and quantified tyrosine hydroxylase-immunoreactive neurons in the substantia nigra pars compacta.
Main Results:
- Heterozygous COX-2-deficient mice exhibited lower mortality following MPTP injection compared to wild-type mice.
- MPTP-treated wild-type mice showed a greater decline in dopaminergic neurons than heterozygous mice.
- Inhibition of COX-2 expression reduced MPTP-induced neurodegeneration and protected dopaminergic neurons.
Conclusions:
- COX-2 plays a significant role in the neurotoxic effects of MPTP.
- Inhibiting COX-2 demonstrates potential as a therapeutic strategy for Parkinson's disease by protecting dopaminergic neurons.
